The Risk of revision after primary total hip arthroplasty among statin users: A nationwide population-based nested case-control study

Journal of Bone and Joint Surgery

Volumn 92, Issue 5, 2010, Pages 1063-1072

  Thillemann, Theis M ^a   Pedersen, Alma B ^a   Mehnert, Frank ^a   Johnsen, Søren P ^a   Søballe, Kjeld ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG USE; ENDOPROSTHESIS LOOSENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSTHESIS INFECTION; RISK FACTOR; SCHOOL CHILD; TOTAL HIP PROSTHESIS; AGED; ARTHROPATHY; CARDIOVASCULAR DISEASE; DENMARK; HIP ARTHROPLASTY; MIDDLE AGED; PROPENSITY SCORE; REGISTER; REOPERATION; RISK; STATISTICAL MODEL; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHILD; DENMARK; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JOINT DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPENSITY SCORE; REGISTRIES; REOPERATION; RISK; RISK FACTORS; YOUNG ADULT;

EID: 77952516350     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.H.01805     Document Type: Article

References (30)

1. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med. 2000;32:164-76.
2. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-9.
3. Oxlund H, Dalstra M, Andreassen TT. Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int. 2001;69:299-304.
4. von Knoch F, Wedemeyer C, Heckelei A, Saxler G, Hilken G, Brankamp J, Sterner T, Landgraeber S, Henschke F, Löer F, von Knoch M. Promotion of bone formation by simvastatin in polyethylene particle-induced osteolysis. Biomaterials. 2005;26:5783-9.
5. Skoglund B, Forslund C, Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res. 2002;17:2004-8.
6. Garrett IR, Gutierrez GE, Rossini G, Nyman J, McCluskey B, Flores A, Mundy GR. Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J Orthop Res. 2007;25:1351-7.
7. Gutierrez GE, Lalka D, Garrett IR, Rossini G, Mundy GR. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos Int. 2006;17:1033-42.
8. Toh S, Hernández-Díaz S. Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf. 2007;16:627-40.
9. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone. 2007;40:1581-7.
10. Laing AJ, Dillon JP, Mulhall KJ, Wang JH, McGuinness AJ, Redmond PH. Statins attenuate polymethylmethacrylate-mediated monocyte activation. Acta Orthop. 2008;79:134-40.
11. Havelin LI, Engesaeter LB, Espehaug B, Furnes O, Lie SA, Vollset SE. The Norwegian Arthroplasty Register: 11 years and 73,000 arthroplasties. Acta Orthop Scand. 2000;71:337-53.
12. Lucht U. The Danish Hip Arthroplasty Register. Acta Orthop Scand. 2000;71:433-9.
13. Pedersen A, Johnsen S, Overgaard S, Søballe K, Sørensen HT, Lucht U. Registration in the Danish Hip Arthroplasty Registry: completeness of total hip arthroplasties and positive predictive value of registered diagnosis and postoperative complications. Acta Orthop Scand. 2004;75:434-41.
14. Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287:2398-9.
15. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-8.
16. Coca-Perraillon M. Local and global propensity score matching. SAS Global Forum 2007. Paper 185-2007. www2.sas.com/proceedings/forum2007/185-2007.pdf. Accessed 2010 Mar 1.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
18. Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001;2:169-88.
19. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol. 2002;53:375-8.
20. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006;59:819-28.
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
22. Thillemann TM, Pedersen AB, Mehnert F, Johnsen SP, Søballe K. Use of diuretics and risk of implant failure after primary total hip arthroplasty: a nationwide population-based study. Bone. 2009;45:499-504.
23. Lim LS, Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Ensrud KE; Osteoporotic Fractures in Men (MrOS) Study Group. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med. 2008;168:735-40.
24. Ayukawa Y, Okamura A, Koyano K. Simvastatin promotes osteogenesis around titanium implants. Clin Oral Implants Res. 2004;15:346-50.
25. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 2001;280:874-7.
26. Rejnmark L, Vestergaard P, Mosekilde L. Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Calcif Tissue Int. 2006;79:27-36.
27. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;6:82.
28. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, Anzueto A, Pugh JA. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J. 2008;31:611-7.
29. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sørensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med. 2008;168:2081-7.
30. Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest. 2003;124:740-3.